Premaitha will issue Thermo Fisher warrants over 28,938,797 new ordinary shares and a second tranche of warrants in 2018.
For the year ended March 31, the Manchester, UK-based provider of noninvasive prenatal testing reported more than £3.1 million ($4 million) in revenue.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
The firm has seen a small handful of false positives for the test in thousands of samples run since the study, but attributed them to biological features.
The company said that Illumina and Sequenom's NIPT patents are not present in the Middle East, allowing it to sell its Iona test unimpeded.
The acquisition will expand Premaitha's market in Asia, enable it to develop new products, and strengthen its patent position in NIPT.
A hospital lab associated with Mahidol University in Thailand will now offer the firm's Iona test in that country and its neighbors.
By offering NIPT as a secondary screening test, the UK hopes to reduce the number of invasive diagnostic tests and associated miscarriages.
Premaitha said it has sold more than 17,000 of the tests, which is the focus of an ongoing patent-infringement suit, since its launch in early 2015.
During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.